Biotech startup Cellino has teamed with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) foundry.
Powered by Cellino’s AI-driven Nebula technology, this initiative sets the stage for a nationwide network of decentralized biomanufacturing hubs designed to deliver personalized cell and tissue therapies directly at the point of care.
Located at Mass General, the foundry — a fully integrated, on-site facility that manufactures patient-specific stem cells — will leverage the Nebula platform to produce clinical-grade iPSCs and derivative therapies with precision and scalability for clinical-grade manufacturing. Nebula is a closed cassette advanced biomanufacturing system that is autonomous and deployable at the point of care, ensuring robust, reproducible and contamination-free production.
The foundry’s first clinical application will be a phase 1 trial focused on a novel Parkinson’s therapy using patient-specific iPSCs.
By eliminating the need to cryopreserve cells and transport them to centralized facilities, a POC manufacturing model could reduce vein-to-vein time and improve outcomes. Read more about efforts to develop decentralized and point of care models in our recent cover story, Within reach.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!